Showing results (81-90 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Medicine|March 28, 2026
Associations of Tumor Somatic Mutations and Genetic Alterations with Survival Outcomes in Melanoma Patients Treated with IpilimumabMohammad Ali Khaksar, Islam Eljilany, Ibrahim Yassine, et al.
Melanoma Research|May 11, 2017
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanomaAhmad A Tarhini, Stergios J Moschos, Yan Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2013
ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)Ronald S Go, Sandra J Lee, Donghoon Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal originAhmad A Tarhini, Paul Frankel, Kim A Margolin, et al.
Cancers|February 27, 2026
Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-AnalysisIslam Eljilany, Eissa Jafari, Abdullah Alhumaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2012
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysisH A Tawbi, J H Beumer, A A Tarhini, et al.
BMJ Oncology|April 13, 2026
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparisonDavid M Miller, James W Smithy, Jennell Palaia, et al.
Frontiers in Oncology|December 19, 2022
Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanomaAhmad A Tarhini, Wissam B Hanayneh, John J Powers, et al.
Cancer|January 14, 2009
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanomaAhmad A Tarhini, Michael Millward, Paul Mainwaring, et al.
Cancers|June 28, 2023
Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell CarcinomaJulian A Marin-Acevedo, Bethany M Withycombe, Youngchul Kim, et al.
Pageof 18